Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.52 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.51 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044837 | 0.87 | HIF1A (0.61) | SLC29A1 | |
| SCHEMBL218771 | 0.86 | DNPH1 (0.70) | DNPH1TAS1R3TAS1R1P2RX3P2RX2 | |
| SCHEMBL29564165 | 0.86 | DNPH1 (0.70) | DNPH1TAS1R3TAS1R1P2RX3P2RX2 | |
| SCHEMBL31685649 | 0.86 | POLB (0.59) | POLBDNPH1TAS1R3TAS1R1ENPP1 | |
| SCHEMBL31685679 | 0.86 | ADORA3 (0.62) | POLBTAS1R3TAS1R1ENPP1P2RY1 | |
| SCHEMBL9693060 | 0.85 | POLB (0.56) | POLBDNPH1TAS1R3TAS1R1P2RX3 | |
| SCHEMBL19699247 | 0.84 | POLB (0.53) | POLBDNPH1TAS1R3TAS1R1P2RX3 | |
| SCHEMBL19699286 | 0.84 | POLB (0.53) | POLBDNPH1TAS1R3TAS1R1P2RX3 | |
| SCHEMBL19699222 | 0.84 | POLB (0.55) | POLBDNPH1TAS1R3TAS1R1ENPP1 | |
| SCHEMBL19699268 | 0.84 | POLB (0.55) | POLBDNPH1TAS1R3TAS1R1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300170-A1 | HCV VACCINES | INTERCELL AG (AT) | 2011-12-08 | — | — | US | claimed |
| US-20110236414-A1 | Bacterial Polysaccharide-Polypeptide Conjugate Compositions | INTERCELL AG (AT) | 2011-09-29 | — | — | US | claimed |
| JP-4734241-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| EP-2345420-A1 | Use of a TH1 immune response inducing adjuvant for enhancing immune responses | Intercell AG (AT) | 2011-07-20 | — | — | EP | claimed |
| JP-4676426-B2 | — | — | 2011-04-27 | — | — | JP | claimed |
| EP-2275131-A2 | HCV Vaccines | Intercell AG (AT) | 2011-01-19 | — | — | EP | claimed |
| US-7858588-B2 | Immunostimulatory oligodeoxynucleic molecules | INTERCELL AG (AT) | 2010-12-28 | — | — | US | claimed |
| EP-1648502-B1 | HCV VACCINES | INTERCELL AG (AT) | 2010-12-01 | — | — | EP | claimed |
| US-20100297170-A1 | VACCINES | VALNEVA AUSTRIA GMBH (AT) | 2010-11-25 | — | — | US | claimed |
| US-20090155294-A1 | HCV VACCINES | BUSCHLE MICHAEL | 2009-06-18 | — | — | US | claimed |
| US-20060263386-A1 | Vaccine against infections with viral pathogens; an antigen, a peptide and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues | INTERCELL AG (AT) | 2006-11-23 | — | — | US | claimed |
| JP-2006521320-A | — | — | 2006-09-21 | — | — | JP | claimed |
| EP-1648502-A2 | HCV VACCINES | Intercell AG (AT) | 2006-04-26 | — | — | EP | claimed |
| EP-1608402-A1 | IMPROVED VACCINES | Intercell AG (AT) | 2005-12-28 | — | — | EP | claimed |
| US-20050250716-A1 | Immunostimulatory oligodeoxynucleotides | INTERCELL AG | 2005-11-10 | — | — | US | claimed |
| WO-2005004910-A2 | HCV VACCINES | INTERCELL AG (AT) | 2005-01-20 | — | — | WO | claimed |
| US-20040248831-A1 | Immunostimulatory oligodeoxynucleic molecules | INTERCELL AG (AT) | 2004-12-09 | — | — | US | claimed |
| WO-2004084938-A1 | IMPROVED VACCINES | INTERCELL AG (AT) | 2004-10-07 | — | — | WO | claimed |
| EP-1296713-B1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | INTERCELL BIOMEDIZINISCHE FORSCHUNGS & ENTWICKLUNGS GMBH (AT) | 2003-09-17 | — | — | EP | claimed |
| US-20030171321-A1 | Immunostimulatory oligodeoxynucleotides | VALNEVA AUSTRIA GMBH (AT) | 2003-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300170-A1 | HCV VACCINES | HAVCR2, CXCR3, CD81 | POLB 2944/4885DNPH1 2265/4885TAS1R3 4000/4885 |
| US-20100297170-A1 | VACCINES | DDX1, DHX15, DDX5 | POLB 480/4885DNPH1 938/4885TAS1R3 3844/4885 |
| US-20090155294-A1 | HCV VACCINES | HAVCR2, CD81, CD74 | POLB 2293/4885DNPH1 3157/4885TAS1R3 4378/4885 |
| US-20040248831-A1 | Immunostimulatory oligodeoxynucleic molecules | NT5C3B, UMPS, NT5C2 | POLB 64/4885DNPH1 104/4885TAS1R3 4218/4885 |
| US-20050250716-A1 | Immunostimulatory oligodeoxynucleotides | IFNG, TLR9, TSLP | POLB 140/4885DNPH1 1163/4885TAS1R3 4635/4885 |
| US-20110236414-A1 | Bacterial Polysaccharide-Polypeptide Conjugate Compositions | DDOST, NGLY1, DAD1 | POLB 1153/4885DNPH1 633/4885TAS1R3 3811/4885 |
| US-20060263386-A1 | Vaccine against infections with viral pathogens; an antigen, a peptide and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues | DUT, CD74, DDX5 | POLB 612/4885DNPH1 454/4885TAS1R3 4391/4885 |
| US-20030171321-A1 | Immunostimulatory oligodeoxynucleotides | NT5C3B, PNP, UMPS | POLB 59/4885DNPH1 77/4885TAS1R3 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.